Scientific Online Resource System

Bulgarian Review of Ophthalmology

Retinoblastoma – a literature review and our experience

A. Oscar, N. Sergeeva, O. Mladenov, N. Veleva, P. Kemilev, G. Dimitrova

Abstract

Retinoblastoma is the most common malignant eye tumor in children that is lethal if left untreated. The contemporary treatment modalities aim not only to save life, but also to preserve the eyes as an organwith form vision and the wich would greatly reflect on the quality of children’s lives. Historically, enucleation was the first successful therapeutic approach to reduce mortality, followed more than 100 years ago by the radiation therapy as the first attempt to save the eyes. Over the last two decades, conservative treatment of retinoblastoma has undergone an impressive development, allowing complete cure with minimal sequelae when timely diagnosed and treated. Today’s treatment protocol includes combination of selective chemotherapy, radiation therapy, laser therapy and, if necessary, systemic chemotherapy. The goal of this article is to review the up-to-date conservative management of retinoblastoma and to emphasize the importance of general practitions and pediatricians for timely diagnosis.


Keywords

enucleation, ocular tumor, retinoblastoma, selective chemotherapy

Full Text


References

Dilenge D, Ascherl GF Jr. Variations of the ophthalmic and middle meningeal arteries: Relation to the embryonic stapedial artery. Am J Neuroradiol. 1980;1:45-54.

Dillon AB, Douglass A, Jabbour P, Shields CL. Minimal exposure intra arterial chemotherapy for children with retinoblastoma and 13q syndrome. Oman J Ophthalmol. 2016;9:164-6.

Gobin YP, Dunkel IJ, Marr BP et al. Combined, sequential intravenous and intra-arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma. PLoS One. 2012;7:e44322.

Grigorovski N, Lucena E, Mattosinho C et al. Use of intra-arterial chemotherapy for retinoblastoma: Results of a survey. Int J Ophthalmol. 2014;7:726-30.

Hutchinson A, Kaliki S, Shields CL. Two-dose exposure of intra-arterial chemotherapy for group D retinoblastoma. J Pediatr Ophthalmol Strab. 2012;49.

Munier F, Popovic B, Chantada M et al. Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. Alive, with good vision and no comorbidity. Prog Retin Eye Res. 2019, 73:100764, doi: 10.1016/j.preteyeres.2019.05.005.

Manjandavida FP, Stathopoulos C, Zhang J et al. Intra-arterial chemotherapy in retinoblastoma – A paradigm change. Indian J Ophthalmol. 2019;67(6):740-754. doi: 10.4103/ijo.IJO_866_19.

MacCarthy А, Bayne АМ, Draper GJ et al. Non-ocular tumours following retinoblastoma in Great Britain 1951 to 2004. Br J Ophthalmol. 2009; 93:1159-1162.

Shields CL, Mashayekhi A, Au AK et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113(12):2276-80. doi: 10.1016/j.oph-tha.2006.06.018.

Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol. 2006;17(3):228-34. doi:10.1097/01.icu.0000193079.55240.18.

Shields CL, Bas Z, Tadepalli S et al. Long-term (20-year) real-world outcomes of intravenous chemotherapy (chemoreduction) for retinoblastoma in 964 eyes of 554 patients at a single centre. Br J Ophthalmol. 2020 Nov;104(11):1548-1555. doi:10.1136/bjophthalmol-2019-315572.

Shields CL, Manjandavida FP, Lally SE et al. Intra arterial chemotherapy for retinoblastoma in 70 eyes: Outcomes based on the international classification of retinoblastoma. Ophthalmology.2014;121:1453-60.

Shields CL, Kaliki S, Al-Dahmash S et al. Management of advanced retinoblastoma with intravenous chemotherapy, then intra-arterial chemotherapy as alternative to enucleation. Retina.2013;33:2103-9.

Shields CL, Say EA, Pointdujour-Lim R et al. Rescue intra-arterial chemotherapy following retinoblastoma recurrence after initial intra-arterial chemotherapy. J Fr Ophtalmol. 2015;38:542-9.

Shields JA, Shields CL. Clinical Overview: Retinoblstoma, In: Ocular Oncology, Taylor & Francis Group, USA, 2003.

Veleva N. Мonography. Leukocoria – congenital and hereditary pathology.

Wong JR, Tucker MA, Kleinerman RA et al. Reti- noblastoma incidence patterns in the US Surveillance, Epidemiology, and End Results program.

JAMA Ophthalmol. 2014 Apr 1;132(4):478-83.

Yu CL, Tucker MA, Abramson DH et al. Cause-specific mortality in long-term survivors of retinoblastoma. J. Natl. Cancer Inst. 2009, 101, 581-591.

Zhang J, Benavente CA, McEvoy J et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012, 481, 329-334.

Zhao J, Dimaras H, Massey C et al. Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J. Clin. Oncol. 2011, 29,845-851.




DOI: http://dx.doi.org/10.14748/bro.v65i1.7428

Refbacks

Font Size


Article Tools
Email this article (Login required)
About The Authors

A. Oscar
MU – Sofia
Bulgaria

Department of Ophthalmology

N. Sergeeva
MU – Sofia
Bulgaria

Department of Ophthalmology

O. Mladenov
MU – Sofia
Bulgaria

Department of Ophthalmology

N. Veleva
MU – Sofia
Bulgaria

Department of Ophthalmology

P. Kemilev
MU – Sofia
Bulgaria

Department of Ophthalmology

G. Dimitrova
MU – Sofia
Bulgaria

Department of Ophthalmology

|